A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy

详细信息    查看全文

• 作者：Shikha Aggarwal ; MBBS (Hons) ; FRACP^a ; ^b ; ^{dr.saggarwal85@gmail.com} ; Neroli Sunderland ; PhD^c ; Charlene Thornton ; PhD^d ; Bei Xu ; MBBS^b ; Annemarie Hennessy ; MBBS ; FRACP ; PhD^a ; ^b ; ^d ; Angela Makris ; MBBS ; FRACP ; PhD^a ; ^b ; ^d
• 关键词：angiotensin II type 1 receptor antibodies ; placental growth factor ; preeclampsia ; soluble endoglin ; soluble fms-like tyrosine kinase 1
• 刊名：American Journal of Obstetrics and Gynecology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：216
• 期：2
• 页码：170.e1-170.e8
• 全文大小：400 K
• 卷排序：216

文摘

Preeclampsia can be caused by shallow trophoblast invasion and results in endothelial dysfunction. Angiotensin II type 1 receptor antibodies may have a role in both processes. Other angiogenic markers (placental growth factor, soluble fms-like tyrosine kinase-1, and soluble endoglin) have been shown to alter before clinically evident preeclampsia.ObjectiveThe aim of this study is to assess the longitudinal changes and utility of biomarker angiotensin II type 1 receptor antibodies and angiogenic markers in hypertensive disorders of pregnancy, gestational hypertension, and preeclampsia.Study DesignA longitudinal prospective cohort observational study of angiogenic markers and a secondary retrospective case-control study of angiotensin II type 1 receptor antibody changes were conducted. The studies were conducted in a large tertiary metropolitan teaching hospital (Sydney, Australia). Sequential recruitment of women with a singleton pregnancy (N = 351) was undertaken. Plasma concentrations of angiotensin II type 1 receptor antibodies, placental growth factor, soluble fms-like tyrosine kinase-1, and soluble endoglin were measured using validated enzyme-linked immunosorbent assays at 12, 18, 28, 36, and 40 weeks’ gestation and 6 weeks’ postpartum. Clinical, demographic, and pregnancy data were prospectively collected. Pregnancy outcomes were classified as normotensive, gestational hypertension, or preeclampsia. Analyses were carried out using software and significance set at P < .05.ResultsIn all, 351 women were recruited, 17 developed gestational hypertension, and 18 developed preeclampsia. Women with preeclampsia at baseline were heavier (P = .015), were taller (P = .046), and had higher systolic (P = .029) and diastolic (P = .006) blood pressure. The preeclampsia group had higher soluble fms-like tyrosine kinase-1 from ≥28 weeks (P = .003) and lower placental growth factor from 18 weeks (P = .004). Soluble endoglin and angiotensin II type 1 receptor antibodies did not vary over time or between groups. Angiotensin II type 1 receptor antibody (12 weeks) was positively correlated with serum pregnancy associated plasma protein A (P = .008) and human chorionic gonadotrophin (P = .04).ConclusionAngiogenic markers vary longitudinally during pregnancy and placental growth factor and soluble fms-like tyrosine kinase-1 have a role for predicting and diagnosing preeclampsia later in disease. Our data show that angiotensin II type 1 receptor antibodies are not sensitive for disease and hence not useful as a biomarker. Larger studies are required to describe the role and functionality of angiotensin II type 1 receptor antibodies in preeclampsia.